Guggenheim Upgrades Grail to Buy with $100 Target on Galleri’s Market Leadership

Guggenheim upgrades Grail to Buy with a $100 price target, citing Galleri’s strong market position in multi-cancer early detection (MCED) despite ongoing regulatory and reimbursement challenges.